GILEAD SCIENCES, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
GILEAD SCIENCES, INC. (GILD) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $2.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2019-02-26
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-06-30 was $0.00.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2016-03-31 was $2.00M.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2016 was $2.00M, a 84.62% decline from fiscal 2015.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2015 was $13.00M, a 73.47% decline from fiscal 2014.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2014 was $49.00M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $0.00 derived: sum of 2 quarters · filed 2019-02-26 | $0.00 derived: sum of 3 quarters · filed 2019-02-26 | $2.00M 10-K · filed 2019-02-26 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $0.00 derived: sum of 2 quarters · filed 2016-11-07 | $2.00M 10-Q · filed 2016-11-07 | $4.00M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $2.00M 10-Q · filed 2016-08-05 | $4.00M derived: sum of 3 quarters · filed 2018-02-27 | $7.00M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $2.00M 10-Q · filed 2016-05-06 | $4.00M derived: sum of 2 quarters · filed 2018-02-27 | $7.00M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2015-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $5.00M derived: sum of 2 quarters · filed 2018-02-27 | $13.00M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $11.00M 10-Q · filed 2015-11-04 | ||
| 2015-06-30 | $8.00M 10-Q · filed 2015-08-05 | |||
| 2014-12-31 | $49.00M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |